MedTrace Logo

Postmarketing Safety Surveillance European Registry of Crohn's Disease Patients Treated With Remicade or Standard Therapy (MK-2155-035)

NCT00705614 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 2662

Last updated 2017-03-22

Study results available
· View outcomes & findings →

Summary

Prospective, observational, parallel-group, postmarketing safety surveillance registry in participants treated with Remicade or standard therapy for active or fistulizing Crohn's disease (CD). The follow-up period is up to 5 years. The participants in the standard therapy group may switch over to Remicade any time during the follow-up period

Conditions

Interventions

BIOLOGICAL

Remicade

The treating physician will determine the treatment regimen and dose of Remicade.

Sponsors & Collaborators

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2003-07-31
Primary Completion
2013-02-28
Completion
2013-02-28

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00705614 on ClinicalTrials.gov